Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection.

CONCLUSION: Identification of anti-HBs-negative subgroups is critical to improve the cost-effectiveness of prophylactic antiviral therapy in lymphoma patients with resolved HBV infection.
PMID: 31235201 [PubMed - as supplied by publisher]

Source: J Formos Med Assoc - June 20, 2019 Category: General Medicine Authors: Tsou HH, Yang HC, Hsiao CF, Hsiung CA, Liu TW, Chuang MH, Wu HY, Hsu YT, Tsui CW, Chen PJ, Cheng AL, Hsu C, Taiwan Cooperative Oncology Group Tags: J Formos Med Assoc Source Type: research